Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial
Matthay, Michael A, Calfee, Carolyn S, Zhuo, Hanjing, Thompson, B Taylor, Wilson, Jennifer G, Levitt, Joseph E, Rogers, Angela J, Gotts, Jeffrey E, Wiener-Kronish, Jeanine P, Bajwa, Ednan K, Donahoe,Language:
english
Journal:
The Lancet Respiratory Medicine
DOI:
10.1016/S2213-2600(18)30418-1
Date:
November, 2018
File:
PDF, 1.32 MB
english, 2018